Association of histologic and clinical activity with major adverse cardiovascular events in patients with inflammatory bowel disease: A cohort study Show others and affiliations
2025 (English) In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 298, no 6, p. 697-710Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: Inflammatory bowel disease (IBD) is a chronic disorder linked to cardiovascular disease (CVD). However, the impact of histologic and clinical activity on this association remains unclear.
METHODS: We conducted a nationwide cohort study in Sweden involving 59,168 IBD patients diagnosed in 1969-2017 with histologic evaluation and 91,800 patients diagnosed in 1969-2020 with assessment of clinical activity in 2006-2021. The primary outcome was incident major adverse cardiovascular events (MACE), a composite outcome encompassing ischemic heart disease, stroke, and heart failure. Cox proportional hazards model estimated adjusted hazard ratios (aHRs) of MACE and its subcomponents.
RESULTS: We found an increased MACE risk following histologic inflammation (n = 868, incidence rate [IR]: 86.3/10,000 person-years) compared to remission (n = 558, IR = 71.3) (aHR = 1.16 [1.04-1.30]). This excess risk was evident in Crohn's disease (aHR = 1.30 [1.03-1.64]) and ulcerative colitis (aHR = 1.13 [1.01-1.27]). Histologic inflammation was associated with an increased risk of ischemic heart disease, myocardial infarction, ischemic stroke, and heart failure, but not with hemorrhagic stroke. Compared to clinically quiescent IBD, active IBD was associated with an increased MACE risk (IR: 131.4 vs. 93.7; aHR = 1.54 [1.46-1.63]) and all MACE subcomponents. In patients with clinically quiescent IBD, histologic inflammation remained linked to myocardial infarction (aHR = 1.29 [1.06-1.58]) and heart failure (aHR = 1.19 [1.00-1.43]).
CONCLUSION: Both histologic and clinical activities of IBD were associated with an increased MACE risk, suggesting that improved disease control may reduce MACE risk in IBD.
Place, publisher, year, edition, pages Wiley-Blackwell Publishing Inc., 2025. Vol. 298, no 6, p. 697-710
Keywords [en]
MACE, clinical activity, cohort, histologic remission, inflammatory bowel disease
National Category
Gastroenterology and Hepatology
Identifiers URN: urn:nbn:se:oru:diva-124626 DOI: 10.1111/joim.70035 ISI: 001599057200001 PubMedID: 41131885 Scopus ID: 2-s2.0-105021363017 OAI: oai:DiVA.org:oru-124626 DiVA, id: diva2:2009112
Funder Swedish Society for Medical Research (SSMF), PG-23-0315-H-02 Swedish Society of Medicine Ruth and Richard Julin Foundation The Karolinska Institutet's Research Foundation Swedish Heart Lung Foundation
Note Funding Agencies:
This study was supported by SSMF (JS; grant number: PG-23-0315-H-02), European Crohn's and Colitis Organization (ECCO, JS), Swedish Society of Medicine (JS), the Ruth and Richard Julin Foundation (JS), the Karolinska Institutet Research Foundation (JS), Stiftelsen Professor Nanna Svartz fond (JS), and the Swedish Heart Lung Foundation (JFL).
2025-10-272025-10-272026-01-23 Bibliographically approved